![Bruno Bruins](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Aktive Positionen von Bruno Bruins
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Intravacc BV
![]() Intravacc BV BiotechnologyHealth Technology Institute for Translational Vaccinology is a Dutch independent company that partners with clients in vaccine development, from discovery to pilot production to clinical studies. The non-profit company is based in Bilthoven, Netherlands. Intravacc designs and creates the best candidate organisms for vaccine strain, looking for the highest immunity, potency, and production yield. The company substantially reduces the risks and costs involved with developing vaccines by bridging the gap between concept and late-stage clinical studies. Intravacc's upstream processing expertise covers both bacterial and cell cultivation as well as virus propagation in reactors ranging from 1l up to 200l. The company's scientists design, develop, and improve vaccine formulations that are suitable for the intended administration route and stable upon storage. | Direktor/Vorstandsmitglied | 01.01.2021 | - |
Karriereverlauf von Bruno Bruins
Ehemalige bekannte Positionen von Bruno Bruins
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Government of the Netherlands | Minister der Regierung | - | 19.03.2020 |
Statistik
International
Niederlande | 3 |
Operativ
Minister of Government | 1 |
Director/Board Member | 1 |
Sektoral
Government | 2 |
Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Government of the Netherlands | Government |
Intravacc BV
![]() Intravacc BV BiotechnologyHealth Technology Institute for Translational Vaccinology is a Dutch independent company that partners with clients in vaccine development, from discovery to pilot production to clinical studies. The non-profit company is based in Bilthoven, Netherlands. Intravacc designs and creates the best candidate organisms for vaccine strain, looking for the highest immunity, potency, and production yield. The company substantially reduces the risks and costs involved with developing vaccines by bridging the gap between concept and late-stage clinical studies. Intravacc's upstream processing expertise covers both bacterial and cell cultivation as well as virus propagation in reactors ranging from 1l up to 200l. The company's scientists design, develop, and improve vaccine formulations that are suitable for the intended administration route and stable upon storage. | Health Technology |
- Börse
- Insiders
- Bruno Bruins
- Erfahrung